Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Acyl-CoA synthetase long-chain family member 6 (ACSL6) is an **enzyme** that catalyzes the conversion of long-chain fatty acids into acyl-CoA derivatives, a key step enabling their use in lipid synthesis, energy production, and cell signaling[1][4]. ACSL6 is vital for the regulation of lipid partitioning, especially in the brain, skeletal muscle, liver, and retina, directing fatty acids toward either storage or oxidation[1][5][6]. Its activity is implicated in metabolic diseases—linked to triglyceride accumulation, insulin resistance, obesity, fatty liver, and cardiovascular disease—and is involved in the regulation of membrane phospholipids critical to neuronal and visual function[2][5][6]. ACSL6 also participates in gene translocation events in certain leukemias[4]. Loss of ACSL6 function in the retina causes photoreceptor degeneration and impaired vision, highlighting its specialized physiological roles[6].
Enzymes such as ACSL6 are targeted experimentally to modulate lipid metabolism, fatty acid uptake, and storage; inhibition or knockdown leads to altered lipid partitioning and mitochondrial function[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Acyl-CoA synthetase long-chain family member 6 (ACSL6).